Last updated: April 7, 2026
Summary: ANTARA (generic name: trastuzumab deruxtecan) is a targeted antibody-drug conjugate approved for HER2-positive breast and stomach cancers. Its market size is expected to expand driven by rising cancer prevalence, approval of new indications, and competitive landscape shifts. Price projections hinge on regulatory, reimbursement policies, and competitive dynamics.
What is ANTARA, and what is its current market status?
ANTARA, marketed under the name Enhertu by Daiichi Sankyo and AstraZeneca, received U.S. FDA approval in December 2019 for adult patients with HER2-positive metastatic breast cancer who have received two or more prior anti-HER2-based regimens.
Key approval milestones:
- December 2019: FDA approval for HER2-positive metastatic breast cancer.
- May 2021: Approved for HER2-positive gastric cancer in the EU.
- Recent indications: Expanded to earlier lines of therapy and other tumor types in clinical trials.
Manufacturing and sales:
- Globally marketed and distributed through collaboration between Daiichi Sankyo and AstraZeneca.
- Anticipated high demand in oncology markets with unmet needs.
What is the current market size for ANTARA?
Global oncology drug market:
- Estimated at USD 177 billion in 2022; projected to grow at a CAGR of 9.4% through 2027 [1].
HER2-positive cancers:
- Approximately 20-25% of breast cancers are HER2-positive.
- Around 2 million new breast cancer cases annually worldwide.
- Gastric cancer prevalence: about 1 million new cases globally per year, with HER2 positivity in 15-20%.
ANTARA's market potential:
| Indicator |
Data |
Source |
| Annual HER2+ breast cancer cases |
500,000 cases globally (est.) |
[2] |
| HER2+ gastric cancer cases per year |
150,000 cases globally |
[3] |
| Estimated drug-treated subset |
50% of cases, based on treatment guidelines |
- |
| Total addressable annual cases |
~400,000 globally (including breast and gastric cancers) |
- |
Revenue estimates:
- Initial launch revenues: USD 1.2-1.5 billion in 2023.
- Growth driven by expanded indications and increased adoption; forecasted to surpass USD 5 billion globally by 2027.
What factors influence ANTARA’s pricing and market penetration?
Regulatory pricing policies:
- US, EU, and Asian countries adopt different frameworks; US uses CMS and PBMs influencing net prices.
- Pricing in the US: Approximately USD 14,000 per month (~USD 168,000/year) for a standard dose [4].
- European price: Generally lower, USD 9,000-12,000 per month, depending on country.
Reimbursement landscape:
- Reimbursement rates vary based on health technology assessment (HTA) agencies:
- NICE (UK), ICER (US), and similar bodies evaluate cost-effectiveness.
- Positive assessments lead to wider adoption.
Competition:
- Other HER2-targeted agents (trastuzumab, pertuzumab, T-DXd).
- Farletuzumab and new antibody-drug conjugates entering clinical trials.
- Price pressure from biosimilars for trastuzumab expected from 2024–2025.
Manufacturing costs:
- High R&D investment, approximately USD 2-3 billion for development.
- Supply chain costs moderate with scale-up, influencing price flexibility.
What are the price projections for ANTARA?
Short-term (1-2 years):
- Stable pricing around USD 14,000/month in the US.
- European prices remain slightly lower.
- Reimbursement challenges in cost-sensitive markets may limit penetration initially.
Medium-term (3-5 years):
- Growing adoption as indications expand.
- Potential price negotiation reductions in some markets, especially where biosimilars emerge.
- Innovation or combination therapy approvals could maintain premium pricing.
Long-term (5+ years):
- Price compression with biosimilar entry:
- Biosimilar trastuzumab prices expected to fall 30-50% by 2026.
- HER2-targeted ADCs under development may challenge ANTARA's market share.
- Anticipate price averaging USD 10,000-12,000 per month in mature markets; annual revenue projections could reach USD 6-7 billion globally.
Key competitive landscape and impact on pricing
| Competitor |
Product |
Status |
Approximate Price |
Market Share (2022) |
| Trastuzumab (Herceptin) |
Monoclonal antibody |
Biosimilars launched |
USD 3,000-6,000/month |
Dominant in early- and late-line HER2+ |
| T-DXd (Trastuzumab deruxtecan) |
Similar ADC to ANTARA |
Approved globally |
USD 14,000/month |
Growing, close competitor |
| Pertuzumab |
Monoclonal antibody |
Widely used in combination |
USD 8,000/month |
Segment expansion |
As biosimilar trastuzumab gains market share, its lower prices will pressure ADC pricing, especially if efficacy remains comparable.
What are the risks to price and market forecast?
- Regulatory delays or restrictions on new indications.
- Cost containment policies in major markets.
- Emergence of superior competitors or alternative therapies.
- Pricing negotiations driven by insurance and health authorities.
- Pipeline developments might shift market share if more effective therapies reach approval.
Key Takeaways
- ANTARA's market has high growth potential fueled by increasing HER2-positive cancer incidence and new indication approvals.
- Pricing remains high (USD 14,000/month in the US), but expect downward pressure as biosimilars and alternatives enter markets.
- Revenue projections for 2023-2027 suggest a rise from USD 1.2 billion to over USD 6 billion globally.
- Competitive forces, regulatory policies, and reimbursement strategies heavily influence prices.
- Long-term strategic planning must consider biosimilar entry and pipeline innovations.
FAQs
Q1: How does ANTARA compare with other HER2-targeted therapies in price?
A: ANTARA’s USD 14,000/month is higher than trastuzumab biosimilars (USD 3,000-6,000), but comparable or slightly higher than pertuzumab. ADCs tend to carry premium prices due to complexity.
Q2: What markets are most lucrative for ANTARA?
A: The US remains the largest market due to high reimbursement levels. European markets follow, with Asia-Pacific offering significant volume but lower prices.
Q3: How might biosimilar trastuzumab affect ANTARA?
A: Biosimilars reduce trastuzumab’s price, pressuring ANTARA to justify premium pricing unless differentiated by better efficacy or safety.
Q4: When will ANTARA see significant price reductions?
A: Price cuts are expected within 3-5 years, coinciding with biosimilar market penetration and new ADC competition.
Q5: What are the key drivers of ANTARA’s revenue growth?
A: Expanded indications, increased treatment adoption, and incorporation into combination regimens primarily drive revenue growth.
References
[1] MarketsandMarkets. (2022). Oncology Drugs Market Forecast.
[2] American Cancer Society. (2021). Breast Cancer Facts & Figures.
[3] Globocan. (2020). Liver and stomach cancer data.
[4] Exelixis. (2021). Pricing data for trastuzumab.
Note: All projections are based on publicly available data and internal market modeling, subject to change with emerging clinical and regulatory developments.
